Recurrent glioblastoma, sometimes referred to as glioblastoma multiforme or simply
GBM, stands as one of the most aggressive brain tumors known to medical science. It
is a malignancy that relentlessly invades the brain, presenting a formidable challenge
for both patients and healthcare providers. Sometimes, an initial glioblastoma returns to
the original tumor site or elsewhere on the brain or spinal cord, and this phenomenon is
known as recurrent glioblastoma.


Plus Therapeutics is developing a new targeted radiation therapy, Rhenium (186Re)
Obisbemeda, for central nervous system cancers such as Recurrent Glioblastoma.  In
the U.S. ReSPECT-GBM clinical trial, doctors will give Recurrent Glioblastoma patients
a single dose of Rhenium (186Re) Obisbemeda is given to the patient through tiny
tubes placed into the skull by a skilled neurosurgeon. This drug will be administered and
requires only a few days stay in the hospital.


To learn more about the ReSPECT-GBM trial, please visit respect-
trials.com/gbm. (NCT01906385).  

ReSPECT-GBM Patient Story | Jim, Recurrent Glioblastoma Survivor 

Dr. Jim Stockand, a dedicated educator with a PhD in Physiology, has spent the past 24
years inspiring students in the classroom. However, in 2022, his life took an unexpected
turn when he was diagnosed with glioblastoma, an aggressive form of brain cancer.
After undergoing standard treatment, Jim faced a daunting setback when the
glioblastoma recurred just nine months later. In January 2023, Jim took a courageous
step by participating in the ReSPECT-GBM trial for recurrent glioblastoma. The day
after he went home from his single-dose treatment, Jim and his wife were able to take a
7-mile walk together—a cherished activity that he had been unable to enjoy for nearly a
year. 

 Jim’s story is a testament to resilience, hope, and the power of pioneering medical
research. His journey not only highlights the challenges faced by those battling cancer
but also the incredible moments of joy that can emerge in the midst of adversity.